Biogen-Sage’s zuranolone impresses in Phase III postpartum depression trialBusiness, R&D, TherapeuticsSage Therapeutics and Biogen’s zuranolone met its primary and key secondary endpoints in the Phase III SKYLARK study of women with postpartum depression (PPD), the companies announced Monday. Read more October 17, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/03/Appeals-Court-Upholds-Decision-for-Mylan-Generic-of-Biogen-MS-Drug-BioSpace-3-17-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-17 07:30:112022-10-17 10:47:58Biogen-Sage’s zuranolone impresses in Phase III postpartum depression trial
